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Barriers to Achieving Glycemic Targets:
Who Omits Insulin and Why?
I
mproved glycemic control in people
withdiabetesdelaystheonsetandpro-
gression of severe microvascular com-
plications of diabetes (1,2). Despite
advances in pharmacotherapy and diabe-
tes treatment devices and the emphasis
placed on treatment adherence over the
last decade, National Health and Nutri-
tion Examination Survey (NHANES) data
showed45%ofpatientswithdiabetesdid
not achieve glycemic targets of 7% (3).
Although some patients with diabetes
may be undertreated (e.g., inappropriate
treatment regimens, psychosocial issues
that require adjustment in therapeutic
targets), one reason for poor glycemic
control is patients’ difﬁculty in following
treatment prescriptions and recommen-
dations for diabetes self-care.
The number of diabetes medications
prescribed and the number of people us-
ing diabetes medications have increased
exponentially as a result of increasing
prevalence rates in type 2 diabetes.
Insulin is an extremely effective glucose-
lowering treatment that is a medical re-
quirement for type 2 diabetes when the
pancreas fails. Approximately 27% of all
peoplewithdiabetestakeinsulin(4).Sur-
prisingly little is known about factors
related to adherence to medication pre-
scriptions and, more speciﬁcally, inten-
tionalinsulinomissionandhowunderlying
motivations for insulin omission differ by
type of diabetes.
ArecentstudyinthisissueofDiabetes
Care by Peyrot et al. (5) brings this issue
totheforefront.Thepurposeofthisstudy
was to explore the frequency of inten-
tional insulin omission and the factors as-
sociated with this behavior in a sample of
502 U.S. adults self-identiﬁed as taking
insulin by injection to treat either type 1
or type 2 diabetes. Fifty-seven percent of
therespondentsreportedomittinginsulin
injections, with 20% omitting insulin in-
jections regularly. Regression analyses
identiﬁed older age, lower income and
education, type 2 diabetes, poor diet ad-
herence, more frequently prescribed in-
jections, interference with daily activities,
pain, and embarrassment as independent
risk factors for intentional insulin omis-
sion. Separate analyses for respondents
withtype1diabetesandthosewithtype2
diabetes found diet adherence to be a
more prominent correlate among type 1
respondents, whereas age, education, in-
come, pain, and embarrassment were
more prominent among type 2 respon-
dents.Althoughpatientrespondentswere
self-selectedandthesamplewasrelatively
small to determine the national preva-
lence of intentional omission of insulin
doses, the ﬁndings suggest that insulin
omission is a substantial problem in the
clinical care of diabetes. Peyrot et al. also
recommend strategies for addressing
these risk factors to prevent intentional
insulin omission, which can inform clin-
ical practice.
The Peyrot study results are consis-
tent with prior research ﬁnding that pa-
tients with type 2 diabetes have relatively
low levels of adherence to insulin esti-
mated to range from 59% for those in
poor glycemic control to 77% for those in
better control (6–8). One danger is that
physicians treating patients with low ad-
herence may prescribe higher doses of in-
sulintocontrolglucoselevels,whichmay
further escalate the problem and may
place the patient at risk of hypoglycemia
when injections are actually taken. Poor
insulinadherenceisasigniﬁcantproblem
for health care delivery. Patients may be
more likely to adhere to their treatment if
they believe it alleviates their diabetes
symptoms (9). Providers should address
patients’perceptionsofthebeneﬁtsofad-
hering to their treatment.
The point at which insulin treatment
should be initiated for those diagnosed
with type 2 diabetes is under debate with
onenewstudyadvocatingthataninsulin-
metformin treatment regimen be consid-
ered in patients newly diagnosed with
type 2 diabetes (10). This study found
that an insulin-metformin regimen was
effective in newly diagnosed type 2 dia-
betic patients without causing increased
weight gain or hypoglycemia when com-
pared to a metformin regimen (10). Oth-
ers suggest that early insulin therapy
may protect against -cell function de-
cline (11–13). Moreover, the American
Diabetes Association and the European
Association for the Study of Diabetes rec-
ommend the early addition of insulin
therapy for patients not achieving treat-
ment goals (14). The ﬁnding by Peyrot
et al. that pain and embarrassment inﬂu-
ence insulin omission suggests that alter-
nate delivery systems such as an insulin
pen system and better preparation for
starting insulin may be useful for improv-
ing how individuals with type 2 diabetes
take insulin.
However, many physicians and pa-
tients are resistant to initiate insulin ther-
apy with higher rates of physicians
delaying insulin therapy in the U.S. com-
pared with other countries (15). More-
over, U.S. patients hold beliefs of lower
insulin efﬁcacy and higher self-blame/
perceived failure for requiring insulin
(15,16). Physicians need to identify and
addresspatients’beliefsaboutinsulinand
examine their own reluctance to initiate
insulin treatment. Addressing type 2 dia-
betic patients’ concerns about insulin
earlyinthetreatmentmay helpminimize
or prevent psychological insulin resis-
tance and insulin omission. This impor-
tant area needs additional study.
The Diabetes Control and Complica-
tions Trial (DCCT) found that improved
glycemia with intensive insulin treatment
was associated with weight gain (17).
Much of the work thus far on insulin
omission has studied patients with type 1
diabetes, with emphasis on insulin omis-
sion as a dangerous symptom among
women with disordered eating issues
(18). Insulin omission is relatively com-
mon,occurringin31%ofasampleof341
women aged 13–60 years with type 1 di-
abetes; 8.8% of that sample reported fre-
quent omission (19) and 28% in a
younger sample of type 1 patients (20).
Insulin omission is associated with disor-
dered eating, psychological distress, fear
of hypoglycemia, and general regimen
nonadherence (19). It results in poorer
glycemic control, increased rates of acute
and chronic complications, hospital ad-
missions for ketoacidosis, increased risk
for mortality, and shortened life span
(18,20).
The connection between type 1 dia-
betesandeatingdisordersisofconcernas
these are associated with poor glycemic
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sis, and more frequent emergency room
and hospital visits (21–23). A well-
controlled study found that DSM-IV cri-
teria eating disorders were more than
twice as prevalent in female subjects with
type 1 diabetes compared with age-
matched control subjects (24). Restric-
tion or omission of insulin may be an
importantsymptomofaconcurrenteat-
ing disorder; however, other issues may
also drive insulin omission although
usually not to the extent found when
associated with disordered eating. The
complexity of the two conditions re-
quires frequent medical and psychiatric
monitoring.
The term diabulimia, which is be-
comingcommoninthepopularpress,isa
misnomer that may lead to the minimiza-
tion of two very serious illnesses, eating
disorders and type 1 diabetes, which,
when comorbid, can lead to serious con-
sequences of increased morbidity and
mortality.Thistermisbestavoidedasitis
not an ofﬁcial diagnosis. Importantly,
Peyrot et al. show that not all insulin
omission is motivated by weight issues,
and they suggest that the assessment of
attitudes and beliefs about insulin is im-
portant to improve glycemia and diabetes
self-management.
The association of insulin omission
and weight may be different among those
with type 2 diabetes. In the Diabetes At-
titudes, Wishes and Needs (DAWN)
study,25%ofadultswithtype1ortype2
diabetes reported worrying about their
body weight (25). Weight concerns were
associated with being female, less edu-
cated,diagnosisoftype2diabetes,having
more comorbidities, shorter duration of
diabetes, and reported weight gain with
diabetes.Weightconcernswerealsoasso-
ciated with worry about both starting in-
sulin and having hypoglycemia. Whether
weight concerns are precursors of resis-
tance to starting insulin treatment or pre-
cursors of intentional insulin omission
once prescribed is not clear and requires
further study (15). Further, whether type
2 diabetic patients perceive insulin treat-
ment as causing weight gain or insulin
omission as causing weight loss is not
completely clear. Studying such percep-
tions is important for better understand-
ing type 2 diabetic patients’ avoidance of
insulin treatment.
Two additional issues raised by Pey-
rot et al. are the impact of depression and
ethnicity/race.Approximately10–15%of
patients with diabetes suffer from comor-
bid major depression (26,27), and
diabetes nonadherence is further compli-
cated by depression (27,28). Depression
increasestheriskofpoorhealthoutcomes
including diabetes complications (29)
andhyperglycemia(30)andleadstopoor
self-care behaviors including adherence
todiet,exercise,andmedicationprescrip-
tions(28,31,32).Depressivesymptomse-
verity, with or without the diagnosis of
major depression, may impede self-care
behaviors (33). Given the high incidence
ofdepressionindiabetes,furtherresearch
examining a potential relationship be-
tween depressive symptoms and inten-
tional insulin omission is important.
A recent U.S. Department of Veterans
Affairs study found poorer insulin taking
behaviors among African American and
Hispanic patients compared with Cauca-
sians (7). One explanation for poorer
insulin adherence rates in different socio-
demographic groups may be varying dia-
betes treatment beliefs. Lower-income
groups may have more fatalistic beliefs
concerning negative treatment outcomes
leading to ineffective self-care (34). Fur-
ther, variations in health care trust and
perceived discrimination have been doc-
umented in African American patients
(35). Finally, African Americans may be
moreconcernedabouttheharmfulnessof
medicationcomparedwithCaucasianpa-
tients, independent of income, medica-
tion costs, and health literacy, and thus
may be more likely to underuse medica-
tions (36). Peyrot et al. did not ﬁnd any
racial/ethnic differences; however, as
the researchers state, with only 11% Af-
ricanAmericansand11%Hispanicsub-
jects in the sample, the study may not
have had enough statistical power to
detect differences.
In order to continue to improve dia-
betes care and A1C levels, we must un-
derstand both providers’ barriers to
prescribing insulin therapy and patients’
barriers to taking insulin as prescribed.
We also need effective interventions that
are brief, well-validated, and compatible
with providers’ practice patterns and lim-
ited encounter time. Although the study
by Peyrot et al. in the current issue of Di-
abetes Care did not address important is-
sues such as other self-care behaviors,
weightconcerns,theimpactofinsulinde-
livery systems, and survey reliability and
validity, the study serves an important
roleinhighlightingtheavoidanceofinsu-
lin treatment among a large segment of
the diabetic population.
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